

Interactome Biotherapeutics Accepted into MassBio Drive Spring Cohort

CAMBRIDGE, MA, UNITED STATES, March 18, 2025 /EINPresswire.com/ -- Interactome Biotherapeutics, a pioneering biotechnology company focused on Engineered small Extracellular Vesicle Biotherapeutics for Diseases of the Central Nervous System, is proud to announce its acceptance into the prestigious [MassBio Drive Spring Cohort](#). MassBio, the heart of biotechnology in Cambridge, MA, is renowned as the leading organization for early-stage biotech companies, providing access to invaluable resources and expertise to help organizations thrive in the highly competitive biotech industry.

The MassBio Drive program is renowned for its selective entry, attracting an impressive array of applications from innovative biotech companies around the world. Following a challenging selection process, Interactome Biotherapeutics has been chosen to participate in this elite cohort, a pivotal moment in the company's journey to revolutionize targeted Drug Delivery with groundbreaking biotherapeutic solutions.

As part of this transformative program, Interactome Biotherapeutics will engage in eight weeks of intensive support from a diverse team of industry experts. This group comprises leaders in legal, regulatory, business development, investor relations, venture capital, and biotech commercialization who will provide essential mentorship and strategic guidance, empowering Interactome to overcome critical challenges and accelerate its growth trajectory.

A significant highlight of this partnership is the collaboration with [Henry Ford Innovations](#) and [Oxford University Innovation](#). The innovative technologies emerging from these partnerships have been instrumental in shaping Interactome's unique solutions. Key contributors, Michael Chopp from Detroit-based Henry Ford Health and Matthew Wood from Oxford University, have played crucial roles in this process, ensuring that Interactome benefits from the cutting-edge advancements developed in their respective labs.

In addition to the expert support, Interactome Biotherapeutics will receive a non-dilutive stipend from Bristol Myers Squibb, reinforcing the power of collaboration within the biotechnology community. This financial support will enable Interactome to further advance its pioneering research and development initiatives, solidifying its position at the forefront of innovation.

"We are thrilled to be selected for the MassBio Drive Spring Cohort, joining a community of visionary biotech companies and industry leaders," stated Adam Koster, CEO and Co-Founder of

Interactome Biotherapeutics. "This opportunity is a game-changer for us, as it allows us to leverage the extensive expertise and resources of MassBio and its network, accelerating our path to market for our transformative biotherapeutic solutions."

The MassBio Drive program equips early-stage biotech companies with the essential tools, resources, and networks needed to reach their full potential. This initiative serves as a critical stepping stone for Interactome Biotherapeutics as it continues to build momentum in the biotechnology sector.

For more information about MassBio Drive and Interactome Biotherapeutics, please contact:

About MassBio

MassBio is the leading trade association for the Massachusetts biotechnology sector, representing over 1,300 biotechnology, pharmaceutical, medical device, and diagnostics companies. MassBio is dedicated to advancing the understanding of life sciences and fostering innovation through education, networking, and industry advocacy.

About Interactome Biotherapeutics

Interactome Biotherapeutics is a cutting-edge biotech company dedicated to developing Engineered small Extracellular Vesicle Biotherapeutics for Diseases of the Central Nervous System. Interactome is committed to transforming the future of Biotherapeutics that have curative potential where current pharmaceutical standards of care only provide symptom mitigation and do not impact the root cause of disease.

Sheena Toma, FNP-C

Interactome Biotherapeutics Inc

+1 (877) 808 - 1114

[email us here](#)

Visit us on social media:

[LinkedIn](#)

[YouTube](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/794144682>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.